| PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies |
30 |
| Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma |
30 |
| Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy |
14 |
| Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy |
14 |
| Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma |
12 |
| Nivolumab Treatment for Cancers in the HIV-infected Population |
12 |
| Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin |
12 |
| The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis |
12 |
| Myasthenia Gravis Induced by Immune Checkpoint Inhibitors |
11 |
| Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature |
10 |
| Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy |
10 |
| Chimeric Antigen Receptor-modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model |
8 |
| Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control |
8 |
| Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model |
8 |
| Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States |
8 |
| Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases |
8 |
| Anti-alpha FR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against alpha FR-positive Ovarian Cancer |
8 |
| Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma |
7 |
| Incidence and Clinical Impact of Anti-TNF alpha Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey |
7 |
| Diabetes and Blood Glucose Disorders Under Anti-PD1 |
7 |
| Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practice |
7 |
| Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients |
7 |
| Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells |
6 |
| Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma |
6 |
| Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases |
6 |
| A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication |
6 |
| Utilizing T-cell Activation Signals and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma |
5 |
| A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab |
5 |
| NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma |
5 |
| Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature |
5 |
| Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial |
5 |
| Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature |
5 |
| Tumor Regression and Cure Depends on Sustained Th1 Responses |
5 |
| Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer |
5 |
| Adoptive Transfer of Interleukin-21-stimulated Human CD8(+) T Memory Stem Cells Efficiently Inhibits Tumor Growth |
5 |
| Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells |
4 |
| Significance of Immune-related Lipase Increase Induced by Antiprogrammed Death-1 or Death Ligand-1 Antibodies: A Brief Communication |
4 |
| Implication of Highly Cytotoxic Natural Killer Cells for Esophageal Squamous Cell Carcinoma Treatment |
4 |
| Role of Interferon (IFN)alpha in Cocktails for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions |
4 |
| Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions |
4 |
| Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer |
4 |
| In Vitro Killing of Colorectal Carcinoma Cells by Autologous Activated NK Cells is Boosted by Anti-Epidermal Growth Factor Receptor-induced ADCC Regardless of RAS Mutation Status |
4 |
| LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target |
4 |
| The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells |
4 |
| Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product |
4 |
| Early Experience With CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells From Third-party Donors for Pediatric Patients With Severe Viral Infections After Hematopoietic Stem Cell Transplantation |
4 |
| Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer |
4 |
| Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer: A Case Series and Review of the Literature |
3 |
| Identification of a Promiscuous Epitope Peptide Derived From HSP70 |
3 |
| Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation |
3 |
